Fate Therapeutics Inc (NASDAQ:FATE) Insider Trading Activity – General Counsel Sold 25,000 shares of Stock

ME Staff
-
0

Insider Trading Activity For Fate Therapeutics Inc (NASDAQ:FATE)

Cindy Tahl , General Counsel of Fate Therapeutics Inc (NASDAQ:FATE) reportedly Sold 25,000 shares of the company’s stock at an average price of 16.15 for a total transaction amount of $403,750.00 SEC Form

Insider Trading History For Fate Therapeutics Inc (NASDAQ:FATE)

  • On 10/4/2013 Venture Fund Vi Lp Arch, Major Shareholder, bought 833,333 with an average share price of $6.00 per share and the total transaction amounting to $4,999,998.00.
  • On 10/4/2013 John Mendlein, Director, bought 16,667 with an average share price of $6.00 per share and the total transaction amounting to $100,002.00.
  • On 3/31/2014 Daniel D Shoemaker, CTO, sold 8,653 with an average share price of $9.86 per share and the total transaction amounting to $85,318.58.
  • On 4/1/2014 J Scott Wolchko, Insider, sold 20,000 with an average share price of $9.64 per share and the total transaction amounting to $192,800.00.
  • On 4/2/2014 Christian Weyer, Insider, sold 10,000 with an average share price of $9.02 per share and the total transaction amounting to $90,200.00.
  • On 4/4/2014 Peter D Flynn, Insider, sold 5,889 with an average share price of $8.00 per share and the total transaction amounting to $47,112.00.
  • On 5/1/2014 Peter D Flynn, Insider, sold 9,793 with an average share price of $7.07 per share and the total transaction amounting to $69,236.51.

    • Analyst Ratings History For Fate Therapeutics Inc (NASDAQ:FATE)

    • On 3/18/2017 Roth Capital Set Price Target of rating Buy with a price target of $8.00
    • On 9/8/2017 Leerink Swann Reiterated Rating Outperform to Outperform with a price target of $7.00
    • On 12/12/2017 Raymond James Reiterated Rating Buy
    • On 3/6/2018 Wells Fargo & Co Reiterated Rating Outperform with a price target of $10.00 to $19.00
    • On 3/6/2018 BMO Capital Markets Boost Price Target of rating Outperform to Outperform with a price target of $7.00 to $20.00
    • On 3/6/2018 UBS Group Downgraded rating Outperform to Market Perform
    • On 8/1/2018 Citigroup Initiated Coverage of rating Buy with a price target of $20.00

    Recent Trading Activity for Fate Therapeutics Inc (NASDAQ:FATE)
    Shares of Fate Therapeutics Inc closed the previous trading session at with 538900 shares trading hands.